Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.415 USD | +3.21% | -5.29% | +42.06% |
Apr. 23 | Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target | MT |
Mar. 21 | Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.06% | 352M | |
+23.32% | 42.68B | |
-3.06% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.85% | 24.94B | |
-20.06% | 18.96B | |
+29.49% | 12.3B | |
-3.19% | 11.95B | |
-2.53% | 11.55B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures